Condition: Colorectal Cancer · CRC (Colorectal Cancer) · Cancer Cachexia · Sponsor: NGM Biopharmaceuticals, Inc
A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.
This description comes directly from the study's public registry record.
NGM Study Director · 650-727-8800 · NGM120CX@ngmbio.com
Always discuss trial participation with your own doctor first.
| NGM Clinical Study Site | Los Angeles, California, United States | Recruiting |
| NGM Clinical Study Site | Los Angeles, California, United States | Recruiting |
| NGM Clinical Study Site | Santa Rosa, California, United States | Recruiting |
| NGM Clinical Study Site | Margate, Florida, United States | Recruiting |
| NGM Clinical Study Site | Baltimore, Maryland, United States | Recruiting |
| NGM Clinical Study Site | New York, New York, United States | Recruiting |
| NGM Clinical Study Site | Toledo, Ohio, United States | Recruiting |
| NGM Clinical Study Site | Youngstown, Ohio, United States | Recruiting |
| NGM Clinical Study Site | Dallas, Texas, United States | Recruiting |
| NGM Clinical Study Site | Kingwood, Texas, United States | Withdrawn |
| NGM Clinical Study Site | Laredo, Texas, United States | Recruiting |
| NGM Clinical Study Site | Richmond, Virginia, United States | Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07033026